



MEDICAL WANDERING

>95%

of patients are currently
NOT diagnosed

Mean age
at diagnosis is
8 years old

A **CE-marked** *in vitro* diagnostic medical device **used as an aid in the diagnosis** of GLUT1 Deficiency Syndrome (Glut1DS)

Glut1DS, or De Vivo disease, is a **neurometabolic** syndrome caused by a defect in the glucose transporter **GLUT1**, resulting in a **cerebral energy deficit**



Diagnosis should be **sooner rather than later** to ensure proper **brain development**

- ! **Neurodevelopmental disorders**
(intellectual disability or specific mixed neurodevelopmental disorder)
- ! **Epilepsy**
(childhood onset, drug resistance, seizures associated with fasting...)
- ! **Movemental disorders**
(paroxysmal or permanent)
- ! **Abnormal eye movements**
- ! **DEE**
(developmental and epileptic encephalopathy)



Think Glut1DS...

Glut1DS is characterized by a **wide phenotypic spectrum** with one or more symptoms, occurring at all ages



Treatable with a
ketogenic diet (KD)

METAglut1™

Direct quantification of
GLUT1 on erythrocytes

- ✓ A simple blood draw
- ✓ No need for fasting
- ✓ Outpatient or inpatient settings
- ✓ Quick turnaround time (24-72hrs.)
- ✓ Great performance*

Equivalent to glycorrhachia

Sensitivity ≈ 80%

PPV = 90%

Specificity > 99%

NPV = 97%




* Mochel F. et al. Prospective Multicenter Validation of a Simple Blood Test for the Diagnosis of Glut1 Deficiency Syndrome. Neurology. 2023



REIMBURSED
IN FRANCE

Expedites proper patient care

METAglut1™ used as a first line simple test to search for Glut1DS patients



METAglut1™
by METAFORA

METAFORA biosystems

29 rue du Faubourg Saint Jacques, 75014 Paris, FRANCE
100 S. State Street, PO 417, Chicago IL 60603, USA
tel: +33 (0) 9 61 62 65 17
contact@metafora-biosystems.com

www.metafora-biosystems.com

This project has received funding under
European Union's Horizon Europe program,
under Grand Agreement n. 806038

